Search bioRxiv⌕ Search

Biology subjects

Oprea, T. I.

Publications and source records attributed to Oprea, T. I..

11 recordsLinked to original sources

ReproTox-KG: Toxicology Knowledge Graph for Structural Birth Defects

Birth defects are functional and structural abnormalities that impact 1 in 33 births in the United States. Birth defects have been attributed to genetic as well as other factors, but for most birth defects there are no known causes. Small molecule drugs, cosmetics, foods, and environmental pollutants may cause birth defects when the mother is exposed to them during pregnancy. These molecules may interfere with the process of normal fetal development. To characterize associations between small molecule compounds and their potential to induce specific birth abnormalities, we gathered knowledge from multiple sources to construct a reproductive toxicity Knowledge Graph (ReproTox-KG) with an initial focus on associations between birth defects, drugs, and genes. Specifically, to construct ReproTox-KG we gathered data from drug/birth-defect associations from co-mentions in published abstracts, gene/birth-defect associations from genetic studies, drug- and preclinical-compound-induced gene expression data, known drug targets, genetic burden scores for all human genes, and placental crossing scores for all small molecules in ReproTox-KG. Using the data stored within ReproTox-KG, we scored 30,000 preclinical small molecules for their potential to induce birth defects. Querying the ReproTox-KG, we identified over 500 birth-defect/gene/drug cliques that can be used to explain molecular mechanisms for drug-induced birth defects. The ReproTox-KG is provided as curated tables and via a web-based user interface that can enable users to explore the associations between birth defects, approved and preclinical drugs, and human genes.

bioinformatics↗

Illuminating the Druggable Genome through Patent Bioactivity Data

The patent literature is a potentially valuable source of bioactivity data. The SureChEMBL database (https://www.surechembl.org/) is a publicly available large-scale resource that contains compounds extracted on a daily basis from the full text, images and attachments of patent documents, through an automated text and image-mining pipeline. In this paper we describe a process to prioritise 3.7 million life science relevant patents obtained from SureChEMBL, according to how likely they were to contain bioactivity data for potent small molecules on less-studied targets, according to the classification developed by the Illuminating the Druggable Genome (IDG) project. The overall goal was to select a smaller number of patents that could be manually curated and incorporated into the ChEMBL database. We describe the approach taken, the results obtained, and provide some illustrative examples.

bioinformatics↗

DISEASES 2.0: a weekly updated database of disease-gene associations from text mining and data integration

The scientific knowledge about which genes are involved in which diseases grows rapidly, which makes it difficult to keep up with new publications and genetics datasets. The DISEASES database aims to provide a comprehensive overview by systematically integrating and assigning confidence scores to evidence for disease-gene associations from curated databases, genome-wide association studies (GWAS), and automatic text mining of the biomedical literature. Here, we present a major update to this resource, which greatly increases the number of associations from all these sources. This is especially true for the text-mined associations, which have increased by at least 9-fold at all confidence cutoffs. We show that this dramatic increase is primarily due to adding full-text articles to the text corpus, secondarily due to improvements to both the disease and gene dictionaries used for named entity recognition, and only to a very small extent due to the growth in number of PubMed abstracts. DISEASES now also makes use of a new GWAS database, TIGA, which considerably increased the number of GWAS-derived disease-gene associations. DISEASES itself is also integrated into several other databases and resources, including GeneCards/MalaCards, Pharos/TCRD, and the Cytoscape stringApp. All data in DISEASES is updated on a weekly basis and is available via a web interface at https://diseases.jensenlab.org, from where it can also be downloaded under open licenses.

bioinformatics↗

Prevalent mouse phenotypes in the unexplored druggable genome

Among the estimated ~23,000 protein encoding human genes, the class of druggable genes- defined by their ability to bind drug-like compounds- represents an enticing collection of targets for clinical intervention. Yet many if not most of these genes remain poorly understood and understudied. Here we evaluate three major classes of druggable genes (GPCRs, ion channels, and kinases) and found that a third of these remain largely ignored yet display significant mouse phenotypes upon genetic ablation. We show that both well-studied and understudied druggable genes share a similar number and spectrum of phenotypes. Moreover, many of the mouse phenotypes arising from the ablation of both well-studied and understudied druggable genes show similarities with symptoms in rare human diseases. Collectively these data diminish the notion that most poorly studied genes may not be especially important and highlight therapeutic opportunities and potential disease models among poorly characterized druggable genes.

genetics↗

AlphaFold Models Illuminate Half of Dark Human Proteins

We investigate the use of confidence scores to predict the accuracy of a given AlphaFold model for drug discovery. Predicted accuracy is improved by eliminating confidence scores below 80, due to effects of disorder. 95% of models corresponding to a set of recent crystal structures are accurate at the fold level. Conformational discordance in the training set has a more significant effect on accuracy than sequence divergence. We propose criteria for models and residues that are possibly useful for virtual screening, by which AlphaFold provides models for half of understudied (dark) human proteins and two-thirds of residues in those models.

pharmacology and toxicology↗

Supervised learning with word embeddings derived from PubMed captures latent knowledge about protein kinases and cancer

Inhibiting protein kinases (PKs) that cause cancers has been an important topic in cancer therapy for years. So far, almost 8% of more than 530 PKs have been targeted by FDA-approved medications and around 150 protein kinase inhibitors (PKIs) have been tested in clinical trials. We present an approach based on natural language processing and machine learning to the relations between PKs and cancers, predicting PKs whose inhibition would be efficacious to treat a certain cancer. Our approach represents PKs and cancers as semantically meaningful 100-dimensional vectors based on co-occurrence patterns in PubMed abstracts. We use information about phase I-IV trials in ClinicalTrials.gov to construct a training set for random forest classification. In historical data, associations between PKs and specific cancers could be predicted years in advance with good accuracy. Our model may be a tool to predict the relevance of inhibiting PKs with specific cancers.

bioinformatics↗

TIGA: Target illumination GWAS analytics

Genome wide association studies (GWAS) can reveal important genotype-phenotype associations, however, data quality and interpretability issues must be addressed. For drug discovery scientists seeking to prioritize targets based on the available evidence, these issues go beyond the single study. Here, we describe rational ranking, filtering and interpretation of inferred gene-trait associations and data aggregation across studies by leveraging existing curation and harmonization efforts. Each gene-trait association is evaluated for confidence, with scores derived solely from aggregated statistics, linking a protein-coding gene and phenotype. We propose a method for assessing confidence in gene-trait associations from evidence aggregated across studies, including a bibliometric assessment of scientific consensus based on the iCite Relative Citation Ratio, and meanRank scores, to aggregate multivariate evidence. This method, intended for drug target hypothesis generation, scoring and ranking, has been implemented as an analytical pipeline, available as open source, with public datasets of results, and a web application designed for usability by drug discovery scientists, at https://unmtid-shinyapps.net/tiga/.

bioinformatics↗

A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research

MotivationIn the event of an outbreak due to an emerging pathogen, time is of the essence to contain or to mitigate the spread of the disease. Drug repositioning is one of the strategies that has the potential to deliver therapeutics relatively quickly. The SARS-CoV-2 pandemic has shown that integrating critical data resources to drive drug-repositioning studies, involving host-host, hostpathogen and drug-target interactions, remains a time-consuming effort that translates to a delay in the development and delivery of a life-saving therapy. ResultsHere, we describe a workflow we designed for a semi-automated integration of rapidly emerging datasets that can be generally adopted in a broad network pharmacology research setting. The workflow was used to construct a COVID-19 focused multimodal network that integrates 487 host-pathogen, 74,805 host-host protein and 1,265 drug-target interactions. The resultant Neo4j graph database named "Neo4COVID19" is accessible via a web interface and via API calls based on the Bolt protocol. We believe that our Neo4COVID19 database will be a valuable asset to the research community and will catalyze the discovery of therapeutics to fight COVID-19. Availabilityhttps://neo4covid19.ncats.io

systems biology↗

Crowdsourced mapping of unexplored target space of kinase inhibitors

Despite decades of intensive search for compounds that modulate the activity of particular targets, there are currently small-molecules available only for a small proportion of the human proteome. Effective approaches are therefore required to map the massive space of unexplored compound-target interactions for novel and potent activities. Here, we carried out a crowdsourced benchmarking of predictive models for kinase inhibitor potencies across multiple kinase families using unpublished bioactivity data. The top-performing predictions were based on kernel learning, gradient boosting and deep learning, and their ensemble resulted in predictive accuracy exceeding that of kinase activity assays. We then made new experiments based on the model predictions, which further improved the accuracy of experimental mapping efforts and identified unexpected potencies even for under-studied kinases. The open-source algorithms together with the novel bioactivities between 95 compounds and 295 kinases provide a resource for benchmarking new prediction algorithms and for extending the druggable kinome.

biochemistry↗

Autophagy dark genes: Can we find them with machine learning?

Identifying novel genes associated with autophagy (ATG) in man remains an important task for gaining complete understanding on this fundamental physiological process. A machine-learning guided approach can highlight potentially \"missing pieces\" linking core autophagy genes with understudied, \"dark\" genes that can help us gain deeper insight into these processes. In this study, we used a set of 103 (out of 288 genes from the Autophagy Database, ATGdb), based on the presence of ATG-associated terms annotated from 3 secondary sources: GO (gene ontology), KEGG pathway and UniProt keywords, respectively. We regarded these as additional confirmation for their importance in ATG. As negative labels, we used the OMIM list of genes associated with monogenic diseases (after excluding the 288 ATG-associated genes). Data associated with these genes from 17 different public sources were compiled and used to derive a Meta Path/XGBoost (MPxgb) machine learning model trained to distinguish ATG and non-ATG genes (10-fold cross-validated, 100-times randomized models, median AUC = 0.994 +/- 0.0084). Sixteen ATG-relevant variables explain 64% of the total model gain, and 23% of the top 251 predicted genes are annotated in ATGdb. Another 15 genes have potential ATG associations, whereas 193 do not. We suggest that some of these 193 genes may represent \"autophagy dark genes\", and argue that machine learning can be used to guide autophagy research in order to gain a more complete functional and pathway annotation of this complex process.

bioinformatics↗

SmartGraph: A Network Pharmacology Investigation Platform

MotivationDrug discovery investigations need to incorporate network pharmacology concepts while navigating the complex landscape of drug-target and target-target interactions. This task requires solutions that integrate high-quality biomedical data, combined with analytic and predictive workflows as well as efficient visualization. SmartGraph is an innovative platform that utilizes state-of-the-art technologies such as a Neo4j graph-database, Angular web framework, RxJS asynchronous event library and D3 visualization to accomplish these goals.\n\nResultsThe SmartGraph framework integrates high quality bioactivity data and biological pathway information resulting in a knowledgebase comprised of 420,526 unique compound-target interactions defined between 271,098 unique compounds and 2,018 targets. SmartGraph then performs bioactivity predictions based on the 63,783 Bemis-Murcko scaffolds extracted from these compounds. Through several use-cases, we illustrate the use of SmartGraph to generate hypotheses for elucidating mechanism-of-action, drug-repurposing and off-target prediction.\n\nAvailabilityhttps://smartgraph.ncats.io/

bioinformatics↗